• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Eli Lilly (NY: LLY )

    884.48 -1.46 (-0.16%)
    Official Closing Price Updated: 7:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,455,234
    Open 888.83
    Bid (Size) 881.40 (1)
    Ask (Size) 883.37 (2)
    Prev. Close 885.94
    Today's Range 878.87 - 891.27
    52wk Range 516.57 - 972.53
    Shares Outstanding N/A
    Dividend Yield 0.51%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
    HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Eli Lilly's Options: A Look at What the Big Money is Thinking
    Via Benzinga

    Performance

    YTD
    +49.35%
    +49.35%
    1 Month
    -7.53%
    -7.53%
    3 Month
    -2.45%
    -2.45%
    6 Month
    +15.78%
    +15.78%
    1 Year
    +64.31%
    +64.31%

    More News

    Read More
    Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
    Via Investor Brand Network
    Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
    Via Benzinga
    Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
    Via Benzinga
    Is NYSE:LLY a Fit for high Growth Investing Strategies?
    Via Chartmill
    Eli Lilly Unusual Options Activity
    Via Benzinga
    Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
    Via Benzinga
    Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
    Via FinancialNewsMedia
    Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
    Via Benzinga
    Exposures Product Safety
    Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
    Via Benzinga
    This Is the Best Pharma Stock to Invest $1,000 in Right Now
    Via The Motley Fool
    Eli Lilly And Co DCF Valuation: Is The Stock Undervalued?
    Via Talk Markets
    Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
    Via The Motley Fool
    1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
    Via The Motley Fool
    Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
    Via The Motley Fool
    Stocks To Buy And Hold For 5 Years
    Via Talk Markets
    Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
    Via The Motley Fool
    BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
    Via Investor's Business Daily
    Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
    Via The Motley Fool
    Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
    Via Benzinga
    Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
    Via Benzinga
    Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
    Via Benzinga
    Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
    Via Benzinga
    Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.